Senores Pharmaceuticals Share Price Today (SENORES)
TODAY IN ONE LINE
SENORES is little changed at ₹1400.10 on light volume — a quiet consolidation day, supported by recent strong earnings.
With a market cap of ₹6,456.25 Cr., it trades at a P/E of 53.33. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Senores Pharmaceuticals flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 108.9% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 53.4% and Profit up 77.3%
- ●High Capital EfficiencyROCE of 15.1% indicating pricing power
- ●Healthy Operating MarginsOPM is structurally strong at 26.6%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
Red Flags
- ●Promoter Pledging DetectedPledge activity recorded on 17-Feb-2026 12:33
Latest Senores Pharmaceuticals News
What changed recently?
Recent events, corporate actions, and announcements.
Senores Pharmaceuticals Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Senores Pharmaceuticals Limited, framed against the sector median so the premium or discount is obvious at a glance.
Senores Pharmaceuticals Limited trades at a P/E of 53.33× and P/B of 6.94×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Senores Pharmaceuticals Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Senores Pharmaceuticals Limited — derived from the live tape, not yesterday's close.
Senores Pharmaceuticals Limited last traded at ₹1,400.1 with an intraday range of ₹1,342.5–₹1,427.9 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1400.10| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1608.63 | +208.53 | +14.89% |
| R3 | 1523.23 | +123.13 | +8.79% |
| R2 | 1475.57 | +75.47 | +5.39% |
| R1 | 1437.83 | +37.73 | +2.70% |
| PIVOT | 1390.17 | -9.93 | -0.71% |
| CURRENT | 1400.10 | — | — |
| S1 | 1352.43 | -47.67 | -3.40% |
| S2 | 1304.77 | -95.33 | -6.81% |
| S3 | 1267.03 | -133.07 | -9.50% |
| S4 | 1181.63 | -218.47 | -15.60% |
SENORES is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1342.5–₹1419
Trading Inside opening range
Senores Pharmaceuticals Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Senores Pharmaceuticals Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Senores Pharmaceuticals Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,456.25 Cr. and reported EPS of ₹26.36.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 398 | 633 ▲ 58.9% |
| Sales Growth YoY %Derived | — | 58.85% |
| Other Income | 19 | 47 ▲ 144.3% |
| Total Income | 418 | 680 ▲ 62.8% |
| 181 | 252 ▲ 39.3% | |
| Gross ProfitDerived | 218 | 381 ▲ 75.1% |
| Gross Margin %Derived | 54.63% | 60.22% |
| 128 | 213 ▲ 66.3% | |
| EBITDA (Operating Profit)Derived | 90 | 168 ▲ 87.6% |
| OPM %Derived | 22.52% | 26.61% |
| 38 | 56 ▲ 46.6% | |
| Profit Before Tax (PBT) | 71 | 159 ▲ 125.4% |
| 12 | 38 ▲ 207.2% | |
| Effective Tax %Derived | 17.33% | 23.61% |
| Total Profit for Period | 58 | 122 ▲ 108.3% |
| Net Profit (Owner's PAT)Derived | 58 | 122 ▲ 108.3% |
| Net Profit Margin %Derived | 14.65% | 19.21% |
| PAT Growth YoY %Derived | — | 108.31% |
| Earnings Per Share (EPS ₹) | 12.67 | 26.39 ▲ 108.3% |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -4 | 29 ▲ 926.9% |
| Total Expenses (incl. D&A & Interest) | 347 | 521 ▲ 50.1% |
| Material Cost % of RevenueDerived | 23.01% | 18.06% |
| Employee Cost % of RevenueDerived | 15.16% | 17.74% |
| Other Cost % of RevenueDerived | 16.94% | 15.87% |
| Interest Coverage (x)Derived | 3.38x | 5.48x |
| Period | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|
| Revenue from Operations | 398 | 633 ▲ 58.9% | |
| Sales Growth YoY %Derived | — | 58.85% | |
| Other Income | 19 | 47 ▲ 144.3% | |
| Total Income | 418 | 680 ▲ 62.8% | |
181 | 252 ▲ 39.3% | ||
| Gross ProfitDerived | 218 | 381 ▲ 75.1% | |
| Gross Margin %Derived | 54.63% | 60.22% | |
128 | 213 ▲ 66.3% | ||
| EBITDA (Operating Profit)Derived | 90 | 168 ▲ 87.6% | |
| OPM %Derived | 22.52% | 26.61% | |
38 | 56 ▲ 46.6% | ||
| Profit Before Tax (PBT) | 71 | 159 ▲ 125.4% | |
12 | 38 ▲ 207.2% | ||
| Effective Tax %Derived | 17.33% | 23.61% | |
| Total Profit for Period | 58 | 122 ▲ 108.3% | |
| Net Profit (Owner's PAT)Derived | 58 | 122 ▲ 108.3% | |
| Net Profit Margin %Derived | 14.65% | 19.21% | |
| PAT Growth YoY %Derived | — | 108.31% | |
| Earnings Per Share (EPS ₹) | 12.67 | 26.39 ▲ 108.3% | |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -4 | 29 ▲ 926.9% | |
| Total Expenses (incl. D&A & Interest) | 347 | 521 ▲ 50.1% | |
| Material Cost % of RevenueDerived | 23.01% | 18.06% | |
| Employee Cost % of RevenueDerived | 15.16% | 17.74% | |
| Other Cost % of RevenueDerived | 16.94% | 15.87% | |
| Interest Coverage (x)Derived | 3.38x | 5.48x |
Senores Pharmaceuticals segment analysis : revenue and profit mix.
Disclosed business segments at Senores Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Senores Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Senores Pharmaceuticals Limited.
Our AI distills the core fundamental drivers supporting Senores Pharmaceuticals Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Senores Pharmaceuticals Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
TTM EPS grew 108.9% YoY, showcasing exceptional earnings momentum and profitability.
Operating margin 21.67% demonstrates strong cost efficiency and pricing power.
Net margin 18.24% exceeds peer averages, reflecting operational excellence.
Debt-to-equity 0.0037 maintains minimal leverage, ensuring financial stability.
TTM revenue grew 53.4% YoY, indicating strong market demand acceleration.
Key Risks.
P/E ratio 49.64x significantly exceeds peer median, indicating overvaluation risk.
Zero dividend yield offers no income to shareholders, limiting appeal.
Operating cash flow negative ₹26.88 Cr in FY2026 signals liquidity strain.
Stock trading near 52-week high ₹1,509.20, limiting upside potential significantly.
ROCE 15.10% and ROE 13.40% lag peer averages, showing capital inefficiency.
Flip Conditions.
Valuation risk. a P/E above 69 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Senores Pharmaceuticals Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Senores Pharmaceuticals Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Senores Pharmaceuticals Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Senores Pharmaceuticals Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Senores Pharmaceuticals Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Senores Pharmaceuticals Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Senores Pharmaceuticals Limited stood at 41.5% of traded volume, against a 20-day average of 41.5%.
Senores Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings Senores Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Senores Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 154 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Senores Pharmaceuticals Limited has informed the Exchange regarding Submission of Reconciliation of Share Capital Audit Report for the quarter ended…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Senores Pharmaceuticals Limited has informed the Exchange regarding Certificate pursuant to Regulation 74(5) of SEBI (DP)Regulations,2018 for quarter…
Copy of Newspaper Publication
Senores Pharmaceuticals Limited has informed the Exchange regarding copy of Newspaper Publication
Shareholders meeting
Senores Pharmaceuticals Limited has informed the Exchange regarding Postal Ballot Notice
Analysts/Institutional Investor Meet/Con. Call Updates
Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Senores Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Senores Pharmaceuticals has declared, sequenced by announce and record date.
Senores Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Senores Pharmaceuticals insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Senores Pharmaceuticals as reported to SEBI — buying and selling signals from the people who know the business best.
Senores Pharmaceuticals insider activity below tracks 60 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Swapnil Jatin Shah | Insider | 28 Mar 2026 | buy | +1.97 L | ₹16 Cr. | ₹812.00 |
| Viraj Ashokkumar Barot | Insider | 28 Mar 2026 | buy | +49.5 K | ₹4.02 Cr. | ₹812.00 |
| Renosen Pharmaceuticals Private Limited | Insider | 28 Mar 2026 | buy | +7.39 L | ₹60.01 Cr. | ₹812.00 |
| Sangeeta Mukur Barot | Insider | 28 Mar 2026 | buy | +61.5 K | ₹4.99 Cr. | ₹812.00 |
| Ashokbhai Vijaysinh Barot | Insider | 28 Mar 2026 | buy | +1.23 L | ₹9.99 Cr. | ₹812.00 |
| Swapnil Jatin Shah | Insider | 28 Mar 2026 | buy | +1.97 L | ₹16 Cr. | ₹812.00 |
| Viraj Ashokkumar Barot | Insider | 28 Mar 2026 | buy | +49.5 K | ₹4.02 Cr. | ₹812.00 |
| Renosen Pharmaceuticals Private Limited | Insider | 28 Mar 2026 | buy | +7.39 L | ₹60.01 Cr. | ₹812.00 |
| Sangeeta Mukur Barot | Insider | 28 Mar 2026 | buy | +61.5 K | ₹4.99 Cr. | ₹812.00 |
| Ashokbhai Vijaysinh Barot | Insider | 28 Mar 2026 | buy | +1.23 L | ₹9.99 Cr. | ₹812.00 |
About Senores Pharmaceuticals Limited: business, sector, key facts.
What Senores Pharmaceuticals Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Senores Pharmaceuticals Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SENORES, BSE: 544319.
Senores Pharmaceuticals Limited is a pharmaceutical company with a global reach, operating primarily in India, the United States, and Canada, as well as exporting to other international markets. Their business model centers around the development, manufacturing, and sale of a diverse range of pharmaceutical products.
The company's product portfolio is extensive and caters to various therapeutic areas. It includes a wide array of dosage forms, such as tablets, capsules, liquids, dry syrups, and oral rehydration solutions. They also manufacture active pharmaceutical ingredients (APIs), which are the fundamental building blocks of many medications. A significant portion of their production focuses on critical care injectables, particularly within the categories of antibiotics, anti-bacterial, and anti-fungal medications, alongside blood line products. This demonstrates a commitment to providing essential medications for a range of health needs.
Beyond the core manufacturing and sales operations, Senores Pharmaceuticals Limited also offers consulting and licensing services. The nature of these services is not explicitly detailed, but it suggests that the company leverages its expertise and infrastructure to assist other businesses within the pharmaceutical sector. This diversification strengthens their overall market presence and revenue streams.
Founded in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Limited's relatively recent establishment highlights its rapid growth and success within the competitive pharmaceutical industry. The company's international presence and diversified product and service offerings position it for continued expansion and influence in the global healthcare market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Senores Pharmaceuticals Limited (SENORES).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Senores Pharmaceuticals Limited (SENORES)?
The current share price of Senores Pharmaceuticals Limited (SENORES) is ₹1,400.1. Today, the stock has declined by ₹3.90 (0.28%), trading in a range of ₹1,342.5 to ₹1,427.9. The stock opened at ₹1,419 with a trading volume of 3,20,705 shares.
02Is Senores Pharmaceuticals Limited stock a good investment for long-term?
Senores Pharmaceuticals Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,456.25 crores, P/E ratio of 53.33, ROE of 13.40%, and ROCE of 15.10%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Senores Pharmaceuticals Limited stock?
The 52-week high price of Senores Pharmaceuticals Limited (SENORES) is ₹1,509.8, while the 52-week low is ₹601.1. Currently trading at ₹1,400.1, the stock is 87.9% away from its 52-week low and 7.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Senores Pharmaceuticals Limited stock at the current price?
Whether to buy Senores Pharmaceuticals Limited stock at ₹1,400.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 53.33 and P/B ratio of 6.94. Today's performance shows a loss of 0.28%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Senores Pharmaceuticals Limited and when is the next dividend?
Senores Pharmaceuticals Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,400.1, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Senores Pharmaceuticals Limited?
Senores Pharmaceuticals Limited's key financial metrics include: P/E Ratio: 53.33, P/B Ratio: 6.94, ROE: 13.40%, ROCE: 15.10%, Dividend Yield: 0.00%, EPS: ₹26.36, Book Value: ₹235.1, and Debt-to-Equity: 0.37. The company's market cap stands at ₹6,456.25 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Senores Pharmaceuticals Limited stock performing today in the market?
Senores Pharmaceuticals Limited stock opened at ₹1,419 and is currently trading at ₹1,400.1, showing a decline of ₹3.90 (0.28%). The intraday high is ₹1,427.9 and low is ₹1,342.5. The trading volume stands at 3,20,705 shares, indicating moderate market participation today.
08What is the P/E ratio of Senores Pharmaceuticals Limited and what does it indicate?
Senores Pharmaceuticals Limited has a Price-to-Earnings (P/E) ratio of 53.33, which means investors are willing to pay ₹53.33 for every ₹1 of earnings. With an EPS of ₹26.36, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Senores Pharmaceuticals Limited (SENORES) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.